StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
August 31, 2026 9:03 AM
TD Cowen analyst Ritu Baral reiterated a Buy rating and $482.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments